Kanwar evaluated the efficacy of different doses of RTX treatment regimens in patients with pemphigus and observed that although no statistically significant difference was noted in the time required to reach the treatment endpoint between the high-dose (RTX 1,000 mg twice a week) and low-dose groups (RTX 500 mg twice a week), monitoring CD19+ B lymphocytes revealed that the high-dose group maintained a longer B cell clearance status (12 weeks in the high-dose group vs. 4 weeks in the low-dose group), and recurrence was less common and had a longer duration in the low-dose group (28). This evidence concerns the gene CD19 and pemphigus.